ZEJULA Is the Only Once-Daily Oral PARP Inhibitor1-3
Description of Treatment
ZEJULA is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2, which play a role in DNA repair1.
ZEJULA has high bioavailability and extensive tissue distribution, as well as a long half-life1,3
Absolute bioavailability of ~73%, indicating minimal first-pass effect
Concentrates in tissue1
Extensive tissue distribution, with a Vd/F of 1,220 L
Mean half-life of 36 h, allowing for once-daily dosing
Please see Important Safety Information below and full Prescribing Information.